Nemluvio (nemolizumab-ilto) — Medica

Prurigo nodularis

Initial criteria

age ≥ 18 years
≥ 20 identifiable nodular lesions in total on both arms, and/or both legs, and/or trunk
pruritus for ≥ 6 weeks
the prurigo nodularis is NOT medication-induced or secondary to a non-dermatologic condition such as neuropathy or psychiatric disease OR if secondary cause is identified it has been adequately managed according to the prescriber
patient has tried at least one high- or super-high-potency prescription topical corticosteroid applied daily for at least 14 consecutive days with inadequate efficacy according to the prescriber
prescribed by or in consultation with an allergist, immunologist, or dermatologist

patient has already received at least 4 months of therapy with Nemluvio
patient has experienced a beneficial clinical response defined by reduced nodular lesion count OR decreased pruritus OR reduced nodular lesion size

initial 4 months; reauthorization 1 year